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Background: The prognosis of metastatic clear cell renal cell carcinoma (ccRCC) 
vastly improved since the introduction of antiangiogenic-targeted therapy. However, it 
is still unclear which biological processes underlie ccRCC aggressiveness and affect 
prognosis. Here, we checked whether a recently discovered systems biomarker based 
on plasmatic or urinary measurements of glycosaminoglycans (GAGs) aggregated into 
diagnostic scores correlated with ccRCC prognosis.
Methods: Thirty-one patients with a diagnosis of ccRCC (23 metastatic) were pro-
spectively enrolled, and their urine and plasma biomarker scores were correlated to 
progression-free survival (PFS) and overall survival (OS) as either a dichotomous (“Low” 
vs. “High”) or a continuous variable in a multivariate survival analysis.
results: The survival difference between “High”- vs. “Low”-scored patients was sig-
nificant in the case of urine scores (2-year PFS rate = 53.3 vs. 100%, p = 3 × 10−4 
and 2-year OS rate = 73.3 vs. 100%, p = 0.0078) and in the case of OS for plasma 
scores (2-year PFS rate = 60 vs. 84%, p = 0.0591 and 2-year OS rate = 66.7 vs. 90%, 
p = 0.0206). In multivariate analysis, the urine biomarker score as a continuous variable 
was an independent predictor of PFS [hazard ratio (HR): 4.62, 95% CI: 1.66–12.83, 
p = 0.003] and OS (HR: 10.13, 95% CI: 1.80–57.04, p = 0.009).
conclusion: This is the first report on an association between plasma or urine GAG 
scores and the prognosis of ccRCC patients. Prospective trials validating the prognostic 
and predictive role of this novel systems biomarker are warranted.
Keywords: molecular biomarkers, prognostic biomarkers, kidney cancer, systems medicine
inTrODUcTiOn
Approximately 50% of cases of clear cell renal cell carcinoma (ccRCC), the most common form 
of kidney cancer (1), develop metastatic disease, which is usually incurable. In sharp contrast to 
early diagnosed ccRCC, the median survival of metastatic patients is significantly worse (2, 3). 
The introduction of sequential use of tyrosine-kinase inhibitors (sunitinib, pazopanib, sorafenib, 
axitinib, lenvatinib, and cabozantinib) and mTOR inhibitors (temsirolimus and everolimus) as well 
as immunotherapies (interleukin-2 and nivolumab) vastly improved the prognosis of metastatic 
ccRCC, though with large variation in overall survival (OS) (4–8). These differences highlight 
the need to identify the critical biological processes underlying ccRCC aggressiveness in order to 
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discover molecular prognostic markers that can subsequently 
guide the therapeutic choices (9).
To this end, significant advances have been made in the 
elucidation of the molecular complexity of ccRCC progression 
(10–13). Using a systems biology approach, we have recently 
discovered that transcriptional regulation of glycosaminoglycan 
(GAG) biosynthesis is a prominent event in ccRCC, exacerbated 
in metastasis (14). Further, we demonstrated that this regulation 
is mirrored by systemic alterations in subjects’ GAG profile, both 
in urine and plasma. We designed a plasma and/or urine score 
that leverages on the GAG profile. These scores reached up to 
100% accuracy in the detection of metastatic disease in a case 
vs. control pilot study conducted on ccRCC subjects. Because 
of its accuracy and minimal invasiveness, GAG profiling is an 
attractive novel biomarker for ccRCC and an early example of 
systems biomarkers.
The primary goal of this observational study was to under-
stand whether the biomarker score correlated with the prognosis 
of ccRCC patients enrolled in our previous study (14). No pre-
specified hypothesis between biomarker scores and survival were 
made for this exploratory analysis.
sUBJecTs/PaTienTs anD MeThODs
study Design and Patient selection
This study report was written in compliance with the REMARK 
guidelines (15). A prospective and consecutive cohort of 
ccRCC patients had been enrolled in our previous biomarker 
study at the Instituto Oncologico Veneto, IOV-IRCCS, Padova, 
Italy. The series was enrolled between January 2013 and June 
2015. The patient population considered for the present study 
included 31 individuals. Inclusion criteria were as follows: a 
histological diagnosis of ccRCC; any disease stage; patients 
either receiving systemic treatment for metastatic disease or 
on follow-up observation without any evidence of disease; and 
written informed consent. Exclusion criteria were non-clear cell 
subtypes. Assessment of disease status was based on clinical 
examination and on computed tomography or other radiological 
assessments at follow-up. Patients could be receiving different 
types of oncological treatment at the time of enrollment, but we 
previously showed that the biomarker score was independent 
from use or type of drug treatment (14). Patient follow-up period 
ended on December 2015 and median follow-up time (from day 
of sampling to event–death or right censoring) was 2.7 years. All 
patients in this study were examined routinely every 3–6 months 
during the follow-up period at the same clinic. All deaths were 
attributed to metastatic cancer. The study was carried out in 
accordance with the recommendations of the guidelines of the 
Research Ethics Committee of IOV-IRCCS, Padova, Italy and the 
participants provided written informed consent in accordance 
with the Declaration of Helsinki. The present observational study 
was notified to the Institutional Review Board at IOV-IRCCS, 
Padova, Italy on January 2013.
Biomarker Determination
The biomarker score was calculated based on plasma and urine 
samples taken once in the occasion of a follow-up visit. Whole 
blood samples were collected in EDTA-coated tubes. The tubes 
were centrifuged (2,500  g for 15  min at 4°C), and the plasma 
was extracted and collected in a separate tube. Urine samples 
were collected in polypropilene tubes. All samples were stored 
at −80°C until they were shipped for analysis in dry ice. GAG 
measurements were conducted using capillary electrophoresis 
with laser-induced fluorescence, as previously described (16, 17). 
Based on these measurements, the plasma and urine biomarkers 
were scored according to formula derived previously (14) and 
here reported:
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where [6s CS] represents the fraction of the 6-sulfated chondroitin 
sulfate, [4s CS] represents the fraction of the 4-sulfated chondroi-
tin sulfate, [Ns6s HS] represents the fraction of the N-sulfated 
6-sulfated heparan sulfate, [Ns HS] represents the fraction of the 
N-sulfated heparan sulfate, CStot is the total concentration of CS 
(in micrograms per milliliter), and Charge HS is the total fraction 
of sulfated disaccharides of HS. Of 31 patients enrolled, 30 plasma 
and 29 urine samples could be successfully scored. Patients with 
missing scores were omitted from all subsequent analyses.
survival analysis
Survival was calculated as the time between the date of sampling 
and the time of event. The time of event is defined as right censor-
ing (date of last follow-up without the event) or as date of death 
in case of OS and date of progression in case of progression-free 
survival (PFS). Univariate and multivariate survival analyses were 
performed by fitting a Cox proportional hazard model to estimate 
the odds-ratio for the variables of interest and the 95% confidence 
interval. The log-rank statistical test was utilized to determine 
the significance of the regression. Initial candidate variables 
were either the plasma score (two missing data) or the urine 
scores (one missing data), as continuous variables computed as 
per formula above. For each fluid, the scores were also used to 
dichotomize patients into two groups, “Low” vs. “High” score, 
where the median score for that fluid was used as an unbiased 
cut-off. Kaplan–Meier survival curves were fitted for the two 
groups, and the statistical significance for survival difference was 
evaluated using the log-rank test. Two-year survival rates were 
calculated as the survival probability at the start of the time inter-
val that includes the Kaplan–Meier fit for 24 months. In addition, 
we performed two additional exploratory survival analyses. In 
the first case, the analysis was carried out only in the 23 patients 
with metastatic disease, and, in the second case, the analysis was 
repeated by calculating survival as the time between the date of 
start of first-line treatment for metastatic disease (instead of date 
of sample collection) and the time of event (progression or death 
or right censoring).
Further variables were considered for regression of survival 
using a univariate Cox model as above: age (continuous, in 
TaBle 1 | clinicopathological features in the prospective cohort, in all patients (first column) or stratified according to “low” and “high” biomarker 
score in the urine or plasma.
Factors all stratified upon plasma score stratified upon urine score
N = 31 low (N = 15) high (N = 15) low (N = 14) high (N = 15)
age 65 (58–77) 67 (61–80) 63 (56–74) 65 (56–74) 65 (58–77)
gender
Female 9 7 2 6 3
Male 22 8 13 8 12
BMi 23.6 (22.5–26.7) 23.2 (23.1–24.5) 26.1 (22.3–28.1) 23.0 (20.3–23.9) 26.1 (23.3–28.0)
smoking habits
Never smoker 18 9 8 8 9
Ex-smoker 8 1 7 1 6
Presence of metastasis
Yes 23 7 15 6 15
No 8 8 0 8 0
Tumor stage
T1/T1a/T1b 9 7 2 7 2
T2/T2a 10 5 5 3 6
T3> 9 2 6 3 5
N0 16 9 7 8 8
N1 1 0 1 0 1
NX 14 6 6 6 6
Fuhrman tumor grade
Grade 2 14 7 6 5 9
Grade 3 9 4 5 3 5
Grade 4 4 2 2 4 0
ecOg performance status
0 18 10 8 10 7
1 13 5 7 4 8
heng classification
Good 15 10 5 8 6
Intermediate 15 4 10 5 9
neutrophile-to-lymphocite
<3 24 10 13 10 13
≥3 5 3 2 2 2
Biomarker score – 0.25 (0.14–0.67) 1.37 (1.10–1.74) 0.75 (0.54–1.10) 1.49 (1.24–1.87)
Distributions are summarized as median and interquartile ranges in brackets.
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years), Easter Cooperative Oncology Group-ECOG performance 
status (integer, 0–4), Fuhrman grade (categorical, I or II vs. III 
or IV, four missing data), Heng score (6) (categorical, good vs. 
intermediate or poor, one missing data), and the neutrophile-
to-lymphocyte ratio (continuous, two missing data). Missing 
data were omitted. A multivariate Cox model was pre-specified 
using variables reaching statistical significance in the univariate 
analysis. In addition, we constructed a multivariate Cox model 
that featured validated prognostic factors: age and performance 
status. The validity of the proportional hazard assumption was 
checked using a two-sided t-test between transformed survival 
time and the scaled Schoenfeld residuals. The sample size was not 
powered specifically for this study, because no prior knowledge 
on the prognostic value of the plasma/urine scores was available 
for ccRCC or any related pathology at the time of design of the 
pilot study (14). We checked for severe overfitting by performing 
internal validation of the univariate and multivariate models 
using a bootstrapping algorithm (1,000 bootstraps) and observ-
ing the change in Somers’ D rank correlation (Dxy) statistics in 
the original datasets as opposed to the test set. The so-corrected 
Dxy is reported as a metric for the predictive discrimination of 
each individual pre-specified model, where Dxy varies between 0 
(random discrimination) to 1 (perfect discrimination). Statistical 
analyses were performed using the packages survival and rms in 
R programing language, v. 3.2.3. p values <0.05 were considered 
significant.
resUlTs
The prospective cohort comprised of 31 patients. Twenty-three 
patients had metastatic disease and were being treated with 
sunitinib (N =  16), everolimus (N =  3), pazopanib (N =  2), 
axitinib (N =  1), or were not currently treated (N =  1). Eight 
patients had a former diagnosis of ccRCC with no evidence of 
metastatic disease at the time of acquisition of blood and urine 
sample and were thus not treated with antineoplastic drugs. 
Among the 23 patients with metastatic disease, 14 patients had 
not been previously treated with other oncological agents, 5 had 
been previously treated with one line of treatment (of which 1 
with sunitinib), and 1 had been treated with multiple lines of 
treatment (1 missing data). For this cohort, we had previously 
calculated the plasma and urine scores in 29 (93%) and 30 
(97%) patients, respectively (14). The median score was 0.89 
(IQR: 0.33–0.96) for plasma and 1.18 (IQR: 0.88–1.49) for urine. 
FigUre 2 | Kaplan–Meier curves for PFs (left) or Os (right) in ccrcc patients according to plasma biomarker score level. The prospective cohort of 
patients (N = 30) was classified as 15 “Low” (solid) vs. 15 “High” (dashed) biomarker score at the time of sampling.
FigUre 1 | Kaplan–Meier curves for PFs (left) or Os (right) in ccrcc patients according to urine biomarker score level. The prospective cohort of 
patients (N = 29) was classified as 14 “Low” (solid) vs. 15 “High” (dashed) biomarker score at the time of sampling.
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For each fluid, we classified patients as either “Low” or “High” 
depending if the biomarker score was below or above the median 
score, which was chosen a priori as unbiased cut-off. We provide 
a comparison of standard clinicopathologic features between the 
two groups in Table 1. None of the patients scored poor accord-
ing to the Heng model (6).
Kaplan–Meier survival plots for all 31 patients revealed that 
“Low”-scored patients fared better both in terms of PFS and OS 
than “High”-scored patients, both in the case of urine and plasma 
scores. Notably, despite the limited sample size, the difference 
between “High” vs. “Low” scores was statistically significant in 
the case of urine [2-year PFS rate = 53.3 (95% CI: 33.2–85.6%) vs. 
100% (Not estimable), log-rank test p = 3 × 10−4 and 2-year OS 
rate = 73.3 (54.0–99.5%) vs. 100% (Not estimable), p = 0.0078, 
Figure  1] as well as in the case of OS for plasma [2-year PFS 
rate = 60 (39.7–90.7%) vs. 84% (66–100%), p = 0.0591 and 2-year 
OS rate = 66.7 (46.6–95.3%) vs. 90% (73.2–100%), p = 0.0206, 
Figure 2]. When modeled as continuous variables, both scores 
showed a linear and concordant increase in the risk of both PFS 
and OS, albeit significant only in the case of urine scores [hazard 
ratio (HR): 10.13, 95% CI: 1.80–57.04, p = 0.009 and Dxy = 0.66 
for OS; HR: 4.62, 95% CI: 1.66–12.83, p = 0.003 and Dxy = 0.57 for 
PFS]. Estimates for the univariate analysis are reported in Table 2 
for PFS and Table 3 for OS.
We repeated the survival analysis above to evaluate two addi-
tional scenarios: the correlation between biomarker score and 
survival in the subset of patients with current metastatic ccRCC 
diagnosis (excluding eight patients with no evidence of disease); 
and, within this subset, the correlation between the biomarker 
score and survival calculated from the start of first systemic 
therapy. In the first scenario, Kaplan–Meier curves for these 
patients stratified according to either the urine or the plasma 
biomarker score underscored a negative association with PFS and 
OS for “High”-scored patients (Figure 3), although statistically 
TaBle 3 | hazard ratio (hr) for clinical factors and Os (patients with missing scores were omitted).
Factors N (n death) hr Univariate Multivariate
95% ci p-Value hr 95% ci p-Value
age 29 0.98 0.94–1.03 0.508
Fuhrman tumor grade
Grade 2 14 (10) 1
Grade >2 13 (3) 0.85 0.17–4.26 0.844
Performance status
0 18 (7) 1
1 13 (6) 2.06 0.57–7.42 0.268
heng classification
Good 11 (3) 1
Intermediate 14 (7) 2.01 0.52–7.79 0.314
neutrophyle-to-lymphocyte
NLR <3 20 (7) 1
NLR ≥3 4 (3) 4.95 1.15–21.28  0.032 17.77 1.58–200.4   0.020
Urine biomarker score 29 10.13 1.80–57.04  0.009 16.43 2.07–130.5   0.008
Plasma biomarker score 30 2.23 0.79–6.25 0.127
TaBle 2 | hazard ratio (hr) for clinical factors and PFs (patients with missing scores were omitted).
Factors N (n progr.) hr Univariate Multivariate
95% ci p-Value hr 95% ci p-Value
age 29 0.98 0.94–1.03 0.600
Fuhrman tumor grade
Grade 2 14 (7) 1
Grade >2 13 (4) 0.39 0.11–1.41 0.393
Performance status
0 18 (6) 1
1 13 (7) 2.26 0. 75–6.77 0.146
heng classification
Good 11 (6) 1
Intermediate 14 (7) 0.84 0.28–2.53 0.761
neutrophyle-to-lymphocyte
NLR <3 20 (10) 1
NLR ≥3 4 (3) 2.49 0.68–9.20 0.169 6.92 1.09–44.03   0.040
Urine biomarker score 29 4.62 1.66–12.83  0.003 5.38 1.65–17.57   0.005
Plasma biomarker score 30 1.69 0.71–4.01 0.232
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significant only in the case of PFS for urine biomarker [2-year 
PFS rate = 54.5 (31.8–93.6%) vs. 80% (58.7–100%), p = 0.0306]. 
As continuous variables, we confirmed a statistically significant 
negative correlation between urine scores and PFS or OS (HR: 
3.63, 95% CI: 1.20–10.95, p = 0.022 for PFS; HR: 8.40, 95% CI: 
1.41–49.96, p = 0.019 for OS), while results for the plasma scores 
were not statistically significant (HR: 0.94, 95% CI: 0.30–2.90, 
p =  0.912 for PFS; HR: 1.64, 95% CI: 0.49–5.45, p =  0.420 for 
OS). In the second scenario, Kaplan–Meier curves showed that 
“High”-scored patients tended to have worse prognosis in terms 
of PFS and OS even when survival time was calculated from 
the date of treatment start (Figure  4). However, the smaller 
size of this patient subset was underpowered to reach statistical 
significance in the case of urine scores [2-year PFS rate = 54.5 
(31.8–93.6%) vs. 80% (58.7–100%), p =  0.0525 and 2-year OS 
rate =  63.6 (40.7–99.5%) vs. 87.5% (67.3–100%), p =  0.0675] 
as well as plasma scores [2-year PFS rate =  54.5 (31.8–93.6%) 
vs. 81.8% (61.9–100%), p =  0.476 and 2-year OS rate =  63.6 
(40.7–99.5%) vs. 90.9% (75.4–100%), p = 0.113].
We then evaluated the correlation between survival and other 
relevant clinical variables of ccRCC: age, performance status, 
tumor grade, Heng group classification, and the neutrophile-
to-lymphocyte ratio (Tables 2 and 3). No significant rank-based 
internal correlations were observed between these variables and 
the plasma or urine scores, but age was positively associated 
with the performance status. We recovered a significant linear 
increase in the HR for OS (but not PFS) with the neutrophile-to-
lymphocyte ratio greater than 3 (HR: 5.03, 95% CI: 1.16–21.80, 
p  =  0.031). A multivariate analysis on the plasma or urine 
biomarker score adjusted for the neutrophile-to-lymphocyte 
ratio confirmed that the urine biomarker score is an independ-
ent predictor of PFS (HR: 4.62, 95% CI: 1.66–12.83, p = 0.003) 
and OS (HR: 10.13, 95% CI: 1.80–57.04, p =  0.009), while the 
plasma biomarker score showed a similar trend without reaching 
statistical significance (Tables 2 and 3). So-specified multivariate 
models were also statistically significant and showed remarkable 
concordance with survival in the case of urine scores (likelihood 
ratio test p = 0.003 and Dxy = 0.63 for OS, p = 0.005 and Dxy = 0.47 
FigUre 3 | Kaplan–Meier curves for PFs (left) or Os (right) limited to patients with metastatic ccrcc according to the urine (a) or plasma (B) 
biomarker score level. The prospective cohort of patients (N = 23) was classified as “Low” (solid) vs. “High” (dashed) biomarker score at the time of sampling.
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for PFS), yet not for plasma scores (p = 0.053 and Dxy = 0.44 for 
OS, p = 0.224 and Dxy = 0.20 for PFS).
Distinct pre-specified multivariate Cox models that analyzed 
the estimated effects of the plasma or urine score and established 
prognostic factors in ccRCC (age and performance status) also 
provided evidence of statistical associations with survival in the 
case of urine scores (likelihood ratio test p = 0.016 and Dxy = 0.50 
for OS, p = 0.021 and Dxy = 0.48 for PFS). However, the individual 
coefficients for the biomarker scores did not reach statistical 
significance in these models, neither for urine (HR for OS: 4.79, 
95% CI: 0.71–32.09, p =  0.107 and HR for PFS: 3.01, 95% CI: 
0.97–9.35, p = 0.057) nor for plasma (HR for OS: 1.69, 95% CI: 
0.54–5.31, p = 0.362 and HR for PFS: 1.42, 95% CI: 0.51–3.93, 
p = 0.497).
cOnclUsiOn
While metastatic ccRCC is considered invariably incurable, 
patients may reach widely different survival rates according to 
clinical prognostic factors (6). In addition, rare complete responses 
have been reported with current antiangiogenic oncological tar-
geted therapies, with or without metastasectomy (18). Therefore, 
it is crucial to determine which biological processes underlie the 
aggressiveness of ccRCC progression, as these could differentiate 
patients at higher risk and advocate distinct strategies of treat-
ment. In the recent years, several molecular prognostic factors 
have been shown to effectively predict poor prognosis based 
on altered expression of proteins or small molecules (19–21). 
However, these biomarkers typically comprise one or few mol-
ecules and are, hence, unlikely to capture the complexity of the 
key biological processes driving ccRCC aggressiveness. On the 
contrary, these processes emerge from the network of interac-
tions of several biomolecules (22).
In our recent report, we adopted an innovative systems biol-
ogy approach to identify the importance of GAG biosynthesis 
regulation in ccRCC. We discovered that the simultaneous meas-
urements of key GAGs in the plasma and urine effectively capture 
the regulation of this process, and validated the diagnostic value 
of scores of this novel systems biomarker (14). This systems 
biomarker agglomerates measurements at the metabolite level, 
which represents an alternative layer of biological information 
with respect to genetic, protein, or immunological markers, which 
have been extensively investigated as potential novel biomarkers 
for ccRCC (23–25).
In the present study, we aimed to explore the correlation of 
the biomarker scores with PFS and OS in the prospective cohort 
of ccRCC patients enrolled in our previous study. A key limita-
tion of this analysis is the small sample size of our cohort, which 
FigUre 4 | Kaplan–Meier curves for PFs (left) or Os (right) calculated from date of first treatment start for metastatic disease according to the urine 
(a) or plasma (B) biomarker score level. The prospective cohort of patients (N = 23) was classified as “Low” (solid) vs. “High” (dashed) biomarker score at the 
time of sampling.
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could not be powered for survival analysis during the design 
of our previous study because no data on similar prognostic 
biomarkers were available in the public domain. We aimed to 
minimize overfitting by internal validation of the pre-specified 
multivariate Cox models, yet only larger study populations will 
provide more precise estimates of HRs for the biomarker scores. 
Another limitation is that potential technical variabilities in the 
analytical measurements of GAGs were not addressed here; in 
that, these measurements were performed in a single laboratory. 
Finally, our previous study did not find significant correlations 
between the GAG scores and dietary or lifestyle habits (14), 
but this relation could not be further controlled in the present 
analyses, due to limited data points. For analogous reasons, future 
studies should focus on variation on GAG scores attributable to 
removal of primary tumor (nephrectomy or enucleoresection) or 
to the time of appearance of distant metastases, concomitantly or 
subsequently after diagnosis of ccRCC.
Despite these limitations, the strength of the association 
between biomarker scores and survival was so high to reach 
statistical significance in both plasma and urine when patients 
were grouped depending on the median score. As a continuous 
variable, the urine score achieved the strongest correlation with 
poor survival, and in particular for OS (univariate HR =  4.62 
for PFS and 10.13 for OS), even when limited to the sole meta-
static patients (univariate HR = 3.63 for PFS and 8.40 for OS). 
In addition, the urine score was independently associated with 
OS and PFS in the multivariate analysis (multivariate HR = 5.38 
for PFS and 16.43 for OS). The plasma score, on the other hand, 
displayed a weaker trend, which was stronger in the case of OS 
(univariate HR = 1.69 for PFS and 2.23 for OS). Consistent with 
the weaker association, this score, as a continuous variable, never 
reached statistical significance in our cohort. We conjecture that 
the plasma score could still have some prognostic value because 
patients with extreme scores fared worse than patients with low 
scores, as demonstrated by the results when subjects were dichoto-
mized based on the median plasma score (log-rank HR = 3.26 for 
PFS and 7.75 for OS). Taken together, these results constitute first 
time evidence that both the plasma and urine biomarker scores at 
the time of sampling could predict prognosis of ccRCC patients, 
both in terms of OS and PFS, and that there exists a quantitative 
linear increase of the risk with increasing scores. These findings 
demonstrate that our previously discovered GAG-based systems 
biomarker has not only diagnostic potential, but may also have 
also prognostic role.
Current prognostic factors in ccRCC are predominantly based 
on clinical parameters. These include composite scoring systems 
designed to improve the prognostic value of individual factors, 
such as tumor size or grade (26). The Heng group classification 
adopted in our study is an example of such systems (6). An 
inherent disadvantage of these systems is that prognosis is based 
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on risk groups rather than quantitative prognostic variables. 
Nevertheless, no prognostic model based on biomarkers has yet 
been integrated in the routine clinical practice. Limited to blood-
based biomarkers, promising results were shown in connection 
with serum VEGF levels (27) (HR = 1.19 for PFS and 1.39 for 
OS), serum amyloid A (28) (HR = 2.51–2.81 for OS), and serum 
insulin-like growth factor-1 (29) (HR = 0.62 for OS). It was noted 
that these biomarkers could suffer from a number of confound-
ing factors that have no tumor origin (26). For example, VEGF 
levels may be derived from damaged platelets, while amyloid 
A is a renowned marker of trauma and various inflammations. 
Conversely, we and other groups previously provided evidence 
that the increase of GAG levels in ccRCC patients is likely a prod-
uct of the tumor itself (30), possibly due to the upregulation of the 
GAG biosynthetic pathway (14). In addition, the here-reported 
HRs for the urine score were not only predictors of poor survival 
in a continuous an independent fashion, but also of much higher 
magnitude compared to the above mentioned biomarkers (mul-
tivariate HR = 5.38 for PFS and 16.43 for OS). However, these 
values might be inflated by the relatively small sample size, as 
shown by the wide range of the confidence intervals.
The distribution of GAGs scores appeared to be independent 
from other prognostic factors such as age, performance status, 
tumor grade, Heng group classification, and the neutrophile-to-
lymphocyte ratio. Since all 8 non-metastatic ccRCC patients had 
low GAG scores (consistent with the notion that the biomarker 
correlates with disease severity), we performed an additional 
analysis in which only the 23 patients with metastatic disease 
were considered. Once again, GAG score retained its prognostic 
significance, suggesting that the prognostic role of this biomarker 
is likely not an expression of the presence of metastatic disease 
by itself. Finally, even though the samples were taken at dif-
ferent times during patient follow-up, the positive correlation 
with OS measured since date of first systemic treatment for 
advanced disease allow us to hypothesize that the prognostic 
role of the systems biomarkers is independent from the time 
point of assessment.
These biomarkers have several potential advantages, the first 
being the minimal invasiveness of measurements, which enables 
dynamic monitoring of the disease. The biological significance 
of GAGs might be related to the role of these macromolecules in 
the interactions with the extracellular matrix and the activation 
of chemokines (31, 32), both processes being implicated in tumor 
metastasis. For example, altered expression of GAGs was associ-
ated to the differential invasive phenotype between non-invasive 
brain lesions and glioblastoma multiforme (33). We speculate 
that a similar mechanism could apply also to ccRCC; even though 
mechanistic studies are currently missing.
In conclusion, this is the first report correlating the dif-
ferent profiles of plasma and urine GAGs with PFS and OS of 
patients with ccRCC. The results of this exploratory study are too 
preliminary to warrant the clinical utility of the GAG score as 
a prognostic biomarker for ccRCC patients, but provide strong 
rationale to conduct prospective confirmatory clinical studies. 
Overall, capturing the complex expression of GAGs by means of 
a non-invasive systems biomarker opens an exciting field in the 
quest to develop prognostic biomarkers for ccRCC.
aUThOr cOnTriBUTiOns
FG performed statistical analyses. UB, CM, and MM coordinated 
the blood and urine sampling and collected clinical data. FG and 
JN conceived and designed the study. FG wrote the manuscript. 
All the authors edited and approved the manuscript in its final 
form.
FUnDing
This work was financially supported by the Knut and Alice 
Wallenberg Foundation.
reFerences
1. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet (2009) 
373:1119–32. doi:10.1016/S0140-6736(09)60229-4 
2. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic 
and socioeconomic burden of metastatic renal cell carcinoma (mRCC): 
a literature review. Cancer Treat Rev (2008) 34:193–205. doi:10.1016/j.
ctrv.2007.12.001 
3. Wahlgren T, Harmenberg U, Sandström P, Lundstam S, Kowalski J, Jakobsson 
M, et al. Treatment and overall survival in renal cell carcinoma: a Swedish pop-
ulation-based study (2000-2008). Br J Cancer (2013) 108:1541–9. doi:10.1038/
bjc.2013.119 
4. Motzer RJ, Barrios CH, Kim TM, Falcon S, Cosgriff T, Harker WG, et  al. 
Phase II randomized trial comparing sequential first-line everolimus and 
second-line sunitinib versus first-line sunitinib and second-line everolimus in 
patients with metastatic renal cell carcinoma. J Clin Oncol (2014) 32:2765–72. 
doi:10.1200/JCO.2013.54.6911 
5. Larkin J, Paine A, Foley G, Mitchell S, Chen C. First-line treatment in the 
management of advanced renal cell carcinoma: systematic review and network 
meta-analysis. Expert Opin Pharmacother (2015) 16:1915–27. doi:10.1517/14
656566.2015.1058359 
6. Heng DY, Signorovitch J, Swallow E, Li N, Zhong Y, Qin P, et  al. 
Comparative effectiveness of second-line targeted therapies for metastatic 
renal cell carcinoma: a systematic review and meta-analysis of real-world 
observational studies. PLoS One (2014) 9:e114264. doi:10.1371/journal.
pone.0114264 
7. Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, et al. 
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): 
final results from a randomised, open-label, phase 3 trial. Lancet Oncol (2016) 
17:917–27. doi:10.1016/S1470-2045(16)30107-3 
8. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, 
et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl 
J Med (2015) 373:1803–13. doi:10.1056/NEJMoa1510665 
9. Modi PK, Farber NJ, Singer EA. Precision oncology: identifying predictive 
biomarkers for the treatment of metastatic renal cell carcinoma. Transl Cancer 
Res (2016) 5:S76–80. doi:10.21037/tcr.2016.06.05 
10. Gatto F, Nookaew I, Nielsen J. Chromosome 3p loss of heterozygosity is 
associated with a unique metabolic network in clear cell renal carcinoma. 
Proc Natl Acad Sci U S A (2014) 111:E866–75. doi:10.1073/pnas.1319196111 
11. Creighton CJ, Morgan M, Gunaratne PH, Wheeler DA, Gibbs RA, Robertson 
A, et  al. Comprehensive molecular characterization of clear cell renal cell 
carcinoma. Nature (2013) 499(7456):43–9. doi:10.1038/nature12222 
12. Hakimi AA, Reznik E, Lee CH, Creighton CJ, Brannon AR, Luna A, et al. An 
integrated metabolic Atlas of clear cell renal cell carcinoma. Cancer Cell (2016) 
29:104–16. doi:10.1016/j.ccell.2015.12.004 
13. Frew IJ, Moch H. A clearer view of the molecular complexity of clear cell 
renal cell carcinoma. Annu Rev Pathol (2015) 10:263–89. doi:10.1146/
annurev-pathol-012414-040306 
9Gatto et al. Glycosaminoglycan Scores and Kidney Cancer Prognosis
Frontiers in Oncology | www.frontiersin.org November 2016 | Volume 6 | Article 253
14. Gatto F, Volpi N, Nilsson H, Nookaew I, Maruzzo M, Roma A, et  al. 
Glycosaminoglycan profiling in patients’ plasma and urine predicts the occur-
rence of metastatic clear cell renal cell carcinoma. Cell Rep (2016) 15:1822–36. 
doi:10.1016/j.celrep.2016.04.056 
15. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommen-
dations for tumor marker prognostic studies (REMARK): explanation and 
elaboration. PLoS Med (2012) 9:e1001216. doi:10.1371/journal.pmed.1001216 
16. Galeotti F, Coppa GV, Zampini L, Maccari F, Galeazzi T, Padella L, et  al. 
Capillary electrophoresis separation of human milk neutral and acidic 
oligosaccharides derivatized with 2-aminoacridone. Electrophoresis (2014) 
35:811–8. doi:10.1002/elps.201300490 
17. Kottler R, Mank M, Hennig R, Müller-Werner B, Stahl B, Reichl U, et  al. 
Development of a high-throughput glycoanalysis method for the character-
ization of oligosaccharides in human milk utilizing multiplexed capillary gel 
electrophoresis with laser-induced fluorescence detection. Electrophoresis 
(2013) 34:2323–36. doi:10.1002/elps.201300016 
18. Albiges L, Oudard S, Negrier S, Caty A, Gravis G, Joly F, et  al. Complete 
remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clin Oncol 
(2012) 30:482–7. doi:10.1200/JCO.2011.37.2516 
19. Jonasch E, Futreal PA, Davis IJ, Bailey ST, Kim WY, Brugarolas J, et al. State 
of the science: an update on renal cell carcinoma. Mol Cancer Res (2012) 
10:859–80. doi:10.1158/1541-7786.MCR-12-0117 
20. Moch H, Srigley J, Delahunt B, Montironi R, Egevad L, Tan PH. 
Biomarkers in renal cancer. Virchows Arch (2014) 464:359–65. doi:10.1007/
s00428-014-1546-1 
21. Parker AS, Eckel-Passow JE, Serie D, Hilton T, Parasramka M, Joseph RW, 
et al. Higher expression of topoisomerase II alpha is an independent marker 
of increased risk of cancer-specific death in patients with clear cell renal cell 
carcinoma. Eur Urol (2014) 66:929–35. doi:10.1016/j.eururo.2013.12.017 
22. Barabasi AL, Oltvai ZN. Network biology: understanding the cell’s functional 
organization. Nat Rev Genet (2004) 5:101–13. doi:10.1038/nrg1272 
23. Rossi E, Fassan M, Aieta M, Zilio F, Celadin R, Borin M, et al. Dynamic changes 
of live/apoptotic circulating tumour cells as predictive marker of response 
to sunitinib in metastatic renal cancer. Br J Cancer (2012) 107:1286–94. 
doi:10.1038/bjc.2012.388 
24. Maroto P, Rini B. Molecular biomarkers in advanced renal cell carcinoma. Clin 
Cancer Res (2014) 20:2060–71. doi:10.1158/1078-0432.CCR-13-1351 
25. Maruzzo M, Basso U, Diminutto A, Roma A, Zustovich F, Brunello A, et al. 
Role of dose exposure and inflammatory status in a single center, real-world 
analysis of sunitinib in patients with metastatic renal cell carcinoma. Future 
Oncol (2016) 12:909–19. doi:10.2217/fon.16.14 
26. Sun M, Shariat SF, Cheng C, Ficarra V, Murai M, Oudard S, et al. Prognostic 
factors and predictive models in renal cell carcinoma: a contemporary review. 
Eur Urol (2011) 60:644–61. doi:10.1016/j.eururo.2011.06.041 
27. Negrier S, Perol D, Menetrier-Caux C, Escudier B, Pallardy M, Ravaud A, 
et  al. Interleukin-6, interleukin-10, and vascular endothelial growth factor 
in metastatic renal cell carcinoma: prognostic value of interleukin-6 – from 
the Groupe Francais d’Immunotherapie. J Clin Oncol (2004) 22:2371–8. 
doi:10.1200/JCO.2004.06.121 
28. Ramankulov A, Lein M, Johannsen M, Schrader M, Miller K, Loening SA, 
et al. Serum amyloid A as indicator of distant metastases but not as early tumor 
marker in patients with renal cell carcinoma. Cancer Lett (2008) 269:85–92. 
doi:10.1016/j.canlet.2008.04.022 
29. Rasmuson T, Grankvist K, Jacobsen J, Olsson T, Ljungberg B. Serum 
insulin-like growth factor-1 is an independent predictor of prognosis in 
patients with renal cell carcinoma. Acta Oncol (2004) 43:744–8. doi:10.1080/ 
02841860410017260 
30. Ucakturk E, Akman O, Sun X, Baydar DE, Dolgun A, Zhang F, et  al. 
Changes in composition and sulfation patterns of glycoaminoglycans in 
renal cell carcinoma. Glycoconj J (2016) 33:103–12. doi:10.1007/s10719-015- 
9643-1 
31. Afratis N, Gialeli C, Nikitovic D, Tsegenidis T, Karousou E, Theocharis AD, 
et al. Glycosaminoglycans: key players in cancer cell biology and treatment. 
FEBS J (2012) 279:1177–97. doi:10.1111/j.1742-4658.2012.08529.x 
32. Taylor KR, Gallo RL. Glycosaminoglycans and their proteoglycans: host-as-
sociated molecular patterns for initiation and modulation of inflammation. 
FASEB J (2006) 20:9–22. doi:10.1096/fj.05-4682rev 
33. Silver DJ, Siebzehnrubl FA, Schildts MJ, Yachnis AT, Smith GM, Smith AA, 
et al. Chondroitin sulfate proteoglycans potently inhibit invasion and serve as 
a central organizer of the brain tumor microenvironment. J Neurosci (2013) 
33:15603–17. doi:10.1523/JNEUROSCI.3004-12.2013 
Conflict of Interest Statement: FG and JN are listed as inventors in a patent 
application related to the biomarker described in this study. UB, CM, and MM 
declare no conflict of interest.
Copyright © 2016 Gatto, Maruzzo, Magro, Basso and Nielsen. This is an open-access 
article distributed under the terms of the Creative Commons Attribution License (CC 
BY). The use, distribution or reproduction in other forums is permitted, provided the 
original author(s) or licensor are credited and that the original publication in this 
journal is cited, in accordance with accepted academic practice. No use, distribution 
or reproduction is permitted which does not comply with these terms.
